Anxiety & Depression Association of America

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

Purpose

This protocol is a Phase 2 multi-site study which aims to evaluate the safety and effectiveness of MYDAYIS® as adjunctive therapy for adults with bipolar depression. Results from this study WILL NOT be used to contribute to an approval of MYDAYIS ® for this indication.

Condition

Bipolar Depression

Eligibility

Eligible Ages: Between 18 Years and 55 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Male or female between 18 and 55 years of age 2. Bipolar I or II disorder as confirmed by structured diagnostic interview by Axis I of the SCID by DSM-IV-TR. 3. Currently experiencing a major depressive episode unresponsive to stable (i.e. at least 4 weeks) anti-manic mood stabilizers (lithium, valproate) and/or antipsychotic therapy, with or without concomitant antidepressant therapy. 4. Symptom severity score ≥11 on the self-report version of the Quick Inventory for Depressive Symptomatology (QIDS-SR16) or score ≥11 on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) and ≥ 3 on the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale. 5. Patients with a comorbid attention deficit disorder and binge eating disorder will be included. 6. Patients will be allowed to continue with their behavioral treatments (ie. CBT) targeted at their primary diagnosis.

Exclusion Criteria

Ability to provide informed consent and understand fully English and score ≥ 90% on comprehension test questionnaire that reviews study goals. 2. Clinically significant signs of suicidality from any of the following assessments: 1. Response ≥ 4 on MADRS question # 10 2. Response ≥2 on QIDS-C or QIDS-SR question # 12 3. Yes response on Columbia Suicide Severity Scale (CSSR) Question # 3 (ideation without plan or intent) ,Question #4 (ideation with intent, but no plan), or Question # 5 (ideation, intent, and plan) 4. Suicide attempt within the past year, as defined by the Columbia-Suicide Severity Scale 3. Known lifetime history of DSM-IV-TR diagnosis of cocaine or methamphetamine abuse or dependence. Nicotine dependence will be an exception. 4. Positive toxicology screen for drugs of abuse (ie. cocaine, methamphetamine, cannabis, opiates) 5. Known history of prescription abuse of stimulants. 6. Lifetime history of stimulant-induced mania 7. Active abuse or dependence of alcohol, opiates or cannabis that is either current or less than 3 months full remission. 8. Baseline Young Mania Rating Scale (YMRS) score ≥ 8 9. Patients with active psychosis identified by SCID or a diagnosis of schizophrenia, schizoaffective disorder, delusional or schizophreniform disorder. 10. Known hypersensitivity, such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS. 11. Clinically unstable medical disease 12. Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke or other serious cardiovascular problems. 13. ECG with significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation). 14. Uncontrolled hypertension (>160/100) or tachycardia (heart rate >110) 15. History of grand mal seizure; history of febrile seizure as infant permitted 16. Established vasculopathy or history of Raynaud's phenomena 17. Narrow angle glaucoma 18. Patients with end stage renal disease (ESRD). 19. Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor. 20. Tourette's syndrome 21. Women who are pregnant, lactating or of child-bearing potential and not using at least one adequate contraceptive measure (i.e. hormonal contraception-birth control pills-, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse) 22. Men who do not use adequate measures (male condoms).

Study Design

Phase: Phase 2
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Study subjects will be randomized to receive MYDAYIS® or placebo on a 1:1 ratio according to computer-generated coding. Each site will have its own randomization list. Allocation concealment will be achieved by having the research pharmacy perform the randomization, package the study medication, and maintain the integrity of the blinded information throughout the study.

Arm Groups

Arm	Description	Assigned Intervention
Active Comparator Mydayis - Active	MYDAYIS®, Oral administration, dose regimen for Double blind phase and open label phase. 12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days	Drug: Mydayis Extended-Release Capsule Randomized, parallel - group, double-blind, placebo-controlled, flexible-dose adjunctive trial of MYDAYIS® Other names: d-amphetamine / l-amphetamine
Placebo Comparator Placebo	Matching placebo, Oral administration, dose regimen for Double blind phase and open label phase. 12.5 mg x 7 days. 25 mg x 7 days 37.5 mg x 14 days 50 mg daily x 28 days	Drug: Placebo Matching placebo

Recruiting Locations

More Details

Status: Recruiting
Sponsor: Mayo Clinic

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.